• A spin-off from the laboratory of Dr. Gilles PAGES, University of Nice Cote d’Azur (Université de Nice Côte d’Azur) and the Institute for Research on Cancer and Aging (IRCAN) • More than 20 years of internationally recognized cutting-edge research in cancer biology involving tumor angiogenesis and lymphangiogenesis • A platform company with a portfolio of 3 secured patents and 2 expected patents • A pipeline of antibodies against several validated targets in angiogenesis and lymphangiogenesis pathways • Therapeutic applications: metastatic cancers and fibrotic disorders • A team of seasoned scientists and biotech professionals